TCM Group A/S: Major shareholder announcement

Seeking Alpha / 29 minutes ago 1 Views

COMPANY ANNOUNCEMENT

CorVel Announces Revenues and Earnings

3 hours from now
Comstock Releases Shareholder Letter

3 hours from now
Newcap Holding A/S – Periodemeddelelse 1. kvartal 2025

3 hours from now
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated i

3 hours from now
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated i

3 hours from now